Results
|
|
1.
|
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. [electronic resource] by
- Kalmanti, L
- Saussele, S
- Lauseker, M
- Müller, M C
- Dietz, C T
- Heinrich, L
- Hanfstein, B
- Proetel, U
- Fabarius, A
- Krause, S W
- Rinaldetti, S
- Dengler, J
- Falge, C
- Oppliger-Leibundgut, E
- Burchert, A
- Neubauer, A
- Kanz, L
- Stegelmann, F
- Pfreundschuh, M
- Spiekermann, K
- Scheid, C
- Pfirrmann, M
- Hochhaus, A
- Hasford, J
- Hehlmann, R
Producer: 20150803
In:
Leukemia vol. 29
Availability: No items available.
|
|
|
2.
|
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. [electronic resource] by
- Hanfstein, B
- Shlyakhto, V
- Lauseker, M
- Hehlmann, R
- Saussele, S
- Dietz, C
- Erben, P
- Fabarius, A
- Proetel, U
- Schnittger, S
- Krause, S W
- Schubert, J
- Einsele, H
- Hänel, M
- Dengler, J
- Falge, C
- Kanz, L
- Neubauer, A
- Kneba, M
- Stegelmann, F
- Pfreundschuh, M
- Waller, C F
- Spiekermann, K
- Baerlocher, G M
- Pfirrmann, M
- Hasford, J
- Hofmann, W-K
- Hochhaus, A
- Müller, M C
Producer: 20141203
In:
Leukemia vol. 28
Availability: No items available.
|
|
|
3.
|
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). [electronic resource] by
- Hanfstein, B
- Müller, M C
- Hehlmann, R
- Erben, P
- Lauseker, M
- Fabarius, A
- Schnittger, S
- Haferlach, C
- Göhring, G
- Proetel, U
- Kolb, H-J
- Krause, S W
- Hofmann, W-K
- Schubert, J
- Einsele, H
- Dengler, J
- Hänel, M
- Falge, C
- Kanz, L
- Neubauer, A
- Kneba, M
- Stegelmann, F
- Pfreundschuh, M
- Waller, C F
- Branford, S
- Hughes, T P
- Spiekermann, K
- Baerlocher, G M
- Pfirrmann, M
- Hasford, J
- Saußele, S
- Hochhaus, A
Producer: 20121113
In:
Leukemia vol. 26
Availability: No items available.
|
|
|
4.
|
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. [electronic resource] by
- Miranda, M B
- Lauseker, M
- Kraus, M-P
- Proetel, U
- Hanfstein, B
- Fabarius, A
- Baerlocher, G M
- Heim, D
- Hossfeld, D K
- Kolb, H-J
- Krause, S W
- Nerl, C
- Brümmendorf, T H
- Verbeek, W
- Fauser, A A
- Prümmer, O
- Neben, K
- Hess, U
- Mahlberg, R
- Plöger, C
- Flasshove, M
- Rendenbach, B
- Hofmann, W-K
- Müller, M C
- Pfirrmann, M
- Hochhaus, A
- Hasford, J
- Hehlmann, R
- Saußele, S
Producer: 20170829
In:
Leukemia vol. 30
Availability: No items available.
|
|
|
5.
|
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. [electronic resource] by
- Hehlmann, R
- Lauseker, M
- Saußele, S
- Pfirrmann, M
- Krause, S
- Kolb, H J
- Neubauer, A
- Hossfeld, D K
- Nerl, C
- Gratwohl, A
- Baerlocher, G M
- Heim, D
- Brümmendorf, T H
- Fabarius, A
- Haferlach, C
- Schlegelberger, B
- Müller, M C
- Jeromin, S
- Proetel, U
- Kohlbrenner, K
- Voskanyan, A
- Rinaldetti, S
- Seifarth, W
- Spieß, B
- Balleisen, L
- Goebeler, M C
- Hänel, M
- Ho, A
- Dengler, J
- Falge, C
- Kanz, L
- Kremers, S
- Burchert, A
- Kneba, M
- Stegelmann, F
- Köhne, C A
- Lindemann, H W
- Waller, C F
- Pfreundschuh, M
- Spiekermann, K
- Berdel, W E
- Müller, L
- Edinger, M
- Mayer, J
- Beelen, D W
- Bentz, M
- Link, H
- Hertenstein, B
- Fuchs, R
- Wernli, M
- Schlegel, F
- Schlag, R
- de Wit, M
- Trümper, L
- Hebart, H
- Hahn, M
- Thomalla, J
- Scheid, C
- Schafhausen, P
- Verbeek, W
- Eckart, M J
- Gassmann, W
- Pezzutto, A
- Schenk, M
- Brossart, P
- Geer, T
- Bildat, S
- Schäfer, E
- Hochhaus, A
- Hasford, J
Producer: 20171205
In:
Leukemia vol. 31
Availability: No items available.
|